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  Background
 - There is a lack of consistent classification systems and incomplete understanding of mechanisms of 
trigeminal neuropathic pains, with very few randomized controlled trials.
  Trigeminal neuralgia
 - Comprehensive history, examination, imaging studies (i.e., MRI), and measures of pain and quality of life 
are essential. 
 - Carbamazepine is a first-line drug, however, its side effects and drug interactions make it difficult to use 
in practice, while oxcarbazepine shows promise but requires more high-quality trials to show its efficacy.
 - Ablative surgery results in trigeminal nerve injury and gives pain relief for 3–5 years, but is accompanied 
by sensory loss and dysesthesias.
 - Microvascular decompression offers the longest pain-free period and is indicated for patients with 
proven neurovascular compression.
  Trigeminal neuropathic pain
 - Trigeminal neuropathic pain is probably due to trauma of the trigeminal nerve.
 - Management recommendations are based on case series and guidelines for other neuropathic pain 
conditions, with tricyclic antidepressants and anticonvulsants (e.g., gabapentin and pregabalin) as  
first-line therapies.
  Burning mouth syndrome
 - Neuropathic, hormonal and psychological factors are suspected as contributing to its pathophysiology.
 - Secondary causes (local and systemic) of burning mouth must be ruled out to obtain a  
definitive diagnosis.
 - Clonazapam and selective serotonin reuptake inhibitors have been shown to be effective in limited 
randomized controlled trials, with anticonvulsants considered to be another option.
  Future perspective
 - Consistent classification systems, taxonomy and phenotyping of conditions are required.
 - Increased knowledge on pathophysiology and mechanisms will determine the choice of targeted 
therapies for these conditions.
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Neuropathic pain has been recently redefined 
by an international group of experts as pain 
arising as a direct consequence of a lesion or 
disease affecting the somatosensory system [1]. 
There are no universally accepted classification 
systems specifically for facial neuropathic pains. 
In recent years, studies examining the specific 
pathophysio logy of the various trigeminal 
neuropathies or altered neuronal function has 
emerged [2]. With the lack of consistent classifi-
cation system and slowly emerging understand-
ing of mechanisms, the management of indi-
vidual conditions continues to be a challenge 
[3]. There is a lack of data on the incidence and 
prevalence of neuropathic facial pains, however, 
the prevalence of all neuropathic pains has been 
reported to be in the range of 2 to 11% [4–6]. As 
a result of neuropathic pains and their treatment 
side effects, patient impairment in quality of life, 
productivity and excess utilization of healthcare 
resources are common [7,8].
In the International Classif ication of 
Headache Disorders (ICHD-II) cranial neu-
ralgias and central causes of facial pain, the 
following trigeminal neuropathic pains are 
listed trigeminal neuralgia (TN), postherpetic 
neuralgia and nasociliary and supra-orbital 
neuralgia [9]. There is also a section listed as 
“other cranial neuralgias and other centrally 
mediated facial pain”. This classification now 
needs to be updated [10] in view of emerging 
new data [11], which has led to the formation 
of two international taskforce committees 
comprising of multidisciplinary teams. It has 
been suggested that terms such as trigeminal 
neuropathic pain, painful traumatic trigemi-
nal neuropathy traumatically induced neural-
gias (TIN) and atypical odontalgia (AO) are 
being used which have many similar features 
and may all represent forms of neuropathic pain 
[12]. Recently a group of experts under the guid-
ance of ontologists have suggested that a more 
accurate term for those within the oral cavity 
is continuous chronic dento alveolar pain, sub-
dividing those with a known cause from oth-
ers with no known primary cause, with further 
subdivision into those with or without sensory 
change [13]. There would remain a category of 
neuropathic facial pain which would follow 
the same principles as previously suggested [14]. 
There is also increasing evidence that burning 
mouth syndrome (BMS) is a continuous neuro-
pathic pain [15]. Covered elsewhere is a distinct 
category of conditions termed the trigeminal 
autonomic cephalgias, which are neuralgiform 
and primarily affect the first division of the 
trigeminal nerve [16].
Trigeminal neuralgia
Trigeminal neuralgia is an excruciating, uni-
lateral, severe and short-lasting (<2 min) pain 
that may be spontaneous or triggered by gentle, 
innocuous stimuli. Current classification defines 
‘classical’ TN (CTN) (previously idiopathic or 
primary) that may or may not be related to 
neurovascular compression, and comprises the 
majority of cases (>85%) of TN. Secondary 
TN (STN) (previously symptomatic) is the 
rarer form that is attributed to previous trauma, 
pathology (e.g., benign and malignant tumors, 
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cysts, demyelination, A-V malformations) or 
secondary systemic disease [17]. Not recognized 
by the current classification system are ‘atypical’ 
TN (ATN) or type 2 cases, in which there are 
classical features of TN, but also a background 
burning, dull type of pain. Such cases are more 
refractory to treatment. It remains to be seen 
whether these are the same condition, or arise 
from different pathophysiologies. TN has been 
reported to be a rare disorder with reported inci-
dences in the range of 4.5/100,000, slight predi-
lection towards females, and occurrence in the 
50–70-year-old age group [18–20]. However, more 
recent studies suggest high incidences ranging 
from 28 to 12/100,000, but also highlight the 
high level of misdiagnosis, as TN has been fre-
quently confused with dental pathology leading 
to unnecessary dental treatment [19,20]. These 
new data suggest that TN may be more common 
and occur in younger age groups. Differential 
diagnosis of TN includes dental pain, sinusi-
tis, short-lasting unilateral neuralgiform head-
aches with conjunctival injection and tearing 
(SUNCT), its variant SUNA where any auto-
nomic features can occur, and atypical (shorter) 
cluster-tic syndrome [16]. 
The etiology and pathophysiology of TN has 
remained difficult to determine, although it is 
hypothesized that compression of the trigemi-
nal root at or near the dorsal root entry zone 
by a blood vessel is a causative or contributive 
factor. Surgical data have consistently failed to 
provide high quality data linking phentotype, 
MRI findings, operative findings and long-term 
outcome, therefore it is not possible to provide 
conclusive evidence that TN is caused solely by 
compression of the trigeminal nerve. A recent 
study using ultra-high-filed MRI found high 
incidences of neuro vascular compression in 
individuals (92%) with no symptoms of TN 
and so suggests that there are other mecha-
nisms involved [21]. Another suggestion exists 
that arachnoid thickening around the trigemi-
nal nerve root can cause angulation, torsion or 
stretching of the nerve [22]. The most widely 
accepted theory is the ‘ignition hypo thesis’, in 
which pathologic changes or injuries make the 
axons and somata hyperexcitable, resulting in 
synchronized afterdischarge activity that gives 
rise to paroxysmal pain [23], however, with the 
absence of data in human subjects this theory 
has been questioned and challenged. It has been 
suggested that these peripheral abnormalities 
may result in hyperexcitability of nociceptive 
neurons in the trigeminal nucleus and/or other 
central brain areas [24,25]. A recent study using 
functional MRI in a highly selected group 
of CTN patients, some of whom underwent 
Gasserian ganglion surgery, showed that ipsi-
lateral sensitization of the trigerminal nucleus 
(SpV) was no longer present after successful 
surgery [26]. They suggest that SpV activation 
may be specifically linked to evoked pain and 
may represent hyperexcitabilty of nociceptive 
trigeminal neurons. However, in those with 
spontaneous pain or lack of evoked pain who 
still show changes in the somatosensory sys-
tem, psychological factors may be playing a role 
in the maintenance of pain. This would lend 
support to a small study which showed that 
central changes with overactivation of central 
facilitation of trigeminal nociceptive process-
ing occured more frequently in individuals with 
ATN than CTN [27–29]. 
The distinguishing features of CTN are the 
timing of the attacks and the remission periods, 
with spontaneous or evoked attacks of several sec-
onds along the distribution of a nerve branch, fol-
lowed by pain-free periods [30]. Those with ATN 
report longer attacks with a constant, burning, 
dull background pain [31]. In 97% of cases, pain 
is unilateral, mostly involving the second or third 
branch of the trigeminal nerve [32]. In the event 
that the patient reports bilateral pain, further 
investigation is warranted to distinguish from 
STN. Quality of life is impaired, with inability 
to socialize and eat leading to weight loss and 
marked changes noted on measures such as the 
Brief Pain Inventory and EuroQol (EQ-5D) [33]. 
Depression and anxiety is commonly reported, 
with suicidal ideation in extreme cases [34,35]. 
Patients with CTN report no sensory deficits, 
however, quantitative sensory testing will distin-
guish it from STN or other entities, as it has been 
reported that 15–20% of patients also exhibit 
sensory loss in the affected branch [36]. The con-
dition has no autonomic features. MRI is use-
ful to rule out STN, and is used to identify and 
locate nerve compression, however, studies have 
shown that neurovascular compression occurs 
frequently in asymptomatic individuals [21].
Long-term follow-up has shown TN to have 
a course of well-defined periods of pain attacks 
followed by periods of remission. Additionally, 
the prognosis is poor, with approximately 90% 
of patients experiencing increased severity and 
frequency of attacks, accompanied by progressive 
resistance to medical and surgical therapies [37].
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Pharmacologic treatment is the first line 
for TN and this is summarized in Table  1. 
While most evidence of eff icacy exists for 
carbamazepine, a longer acting form of this 
drug has been shown to be useful for night 
use to ensure therapeutic serum levels, and 
decrease side effects from high serum peaks 
[38,39]. For those with significant side effects 
from carbamazepine, dosage may be reduced 
and baclofen (50–80 mg daily) may be added 
as an adjunct. Oxcarbazepine (300–1200 mg 
daily) is a derivative with fewer side effects 
and drug interactions than carbamazepine. 
Among the few studies, it has similar efficacy 
as carbamazepine and better tolerability [40]. 
Lamotrigine (400–600 mg daily) has been 
reported in small case series and a small ran-
domized controlled trial (RCT) as an adjunct 
Table 1. Medical management of trigeminal neuralgia: common treatment modalities.
Drug/procedure/therapy Author (year) Efficacy/comments Adverse effects/morbidity/
mortality
Ref.
Evidence from RCTs
Baclofen (50–80 mg daily) Fromm et al. (1984)
Fromm and Terrence (1987)
Parekh et al. (1989)
Adjunct medication with others
Possibly effective
Three small RCTs
Ataxia, lethargy, fatigue, nausea, 
vomiting, loss of muscle tone
Beware of rapid withdrawal
[24]
[84]
[85]
Carbamazepine  
(300–1000 mg daily)
Campbell et al. (1966)
Killian and Fromm (1968)
Nicol (1969)
NNT 1.9 (95% CI: 1.4–2.8)
Loses efficacy with time
Requires careful monitoring 
for drug interactions, blood 
dyscrasias, electrolytes 
Introduce slowly
Drowsiness, ataxia, headaches, 
poor concentration, nausea, blurred 
vision, rash
[86]
[87]
[88]
Gabapentin  
(300–3600 mg daily)
Lemos et al. (2008) Evaluated in combination with 
ropivacaine only in RCT  
(300–900 mg)
NNT 2.4 (95% CI: 1.46–8.49) in 
combination with ropivacaine
Open trials use higher dosages 
(1800–3600 mg)
Sedation, ataxia, dizziness, edema [89]
Lamotrigine  
(200–400 mg daily)
Zakrzewska et al. (1997) Good when added to other 
antiepileptic drug
NNT 2.1 (95% CI: 1.3–6.1) 
Escalate slowly to avoid rashes
Dizziness, drowsiness, constipation, 
ataxia, diplopia, irritability
[43]
Oxcarbazepine  
(300–1200 mg daily)
Liebel et al. (2001)
Beydoun and Kutluay (2002)
Equal efficacy to carbamazepine 
but better tolerated 
Less tendency for blood 
dyscrasias
No major drug interactions
Drowsiness, poor concentration, 
dizziness, ataxia, nausea
Hyponatremia in high doses
[90]
[91]
No evidence from RCTs
Clonazepam (4–8 mg daily) Caccia (1975)
Chandra (1976)
Court and Kase (1976)
Smirne and Scarlato (1997)
Good to excellent results 
reported in small case series
Addictive tendency 
Lethargy, dizziness, personality 
change
Thrombocytopenia
[92]
[93]
[94]
[95]
Phenytoin  
(200–300 mg daily)
Iannone et al. (1958)
Braham and Saia (1960)
Chinitz et al. (1966)
Good to excellent results 
reported in small case series 
Complex pharmacokinetics 
preclude large dosage changes
Folate deficiency in prolonged use
Ataxia, lethargy, headache
Gingival hyperplasia
[96]
[97]
[98]
Pregabalin  
(150–600 mg daily)
Obermann et al. (2008)
Perez et al. (2009)
Overall 59% response rate in  
two case series, but results  
not sustained
Rapid titration possible and twice 
daily dosage
Dizziness, tiredness, headaches, 
peripheral edema
[99]
[100]
NNT: Number needed to treat; RCT: Randomized controlled trial.
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for subeffective therapy [41–43]. The limited 
evidence for gabapentin in TN showed best 
response among patients who used it in com-
bination with a local anesthetic, but the doses 
used were small and in newly diagnosed patients 
who may have gone into natural remission. 
There currently is insufficient evidence showing 
efficacy of nonantiepileptic drugs (e.g., tizani-
dine, tocainide or pimozide) for the management 
of TN [44].
Patients’ age, medical status and response to 
medical therapy factor into making the deci-
sion to treat surgically [45,46]. However, there is 
insufficient evidence to determine what is the 
most effective surgical intervention due to lack 
of RCTs, cohort studies, uniform criteria and 
outcome measures [47,48]. Surgery can be carried 
out at three different levels: peripherally at trig-
ger points; at the Gasserian ganglion level; and 
at the posterior fossa nerve root level (Table 2). 
All peripheral procedures give only tempo-
rary relief, and have the goal of inducing local-
ized nerve damage and should be reserved for 
emergency use or for patients for whom other 
procedures or treatments are contraindicated. 
There are no recent high quality studies in this 
area [48]. Pain relief varies from a few months 
to 2 years, however, patients often remain on 
some medication after surgery. Procedures at 
the Gasserian ganglion level include radiofre-
quency rhizolysis, glycerol injection or balloon 
compression. They are all destructive (ablative) 
and therefore result in varying sensory loss 
which can affect quality of life. 
Surgeries at the posterior fossa nerve root 
level include stereotactic radiosurgery and 
micro vascular decompression. Stereotactic 
radiosurgery delivers radiosurgical doses of 
70–90 Gray units to the trigeminal nerve root 
at the point of vascular compression, as mapped 
using MRI. Pain relief can be delayed for several 
months and may only be partial. As longer term 
data from larger centers is being published it 
appears that the pain relief time is similar to 
other destructive procedures and sensory loss 
can occur up to 6 months after treatment [49]. 
The procedure of micro vascular decompres-
sion, a major neurosurgical procedure, aims to 
separate the nerve from the suspected compress-
ing vessel without damage to the nerve itself, 
and provides the longest period of pain relief 
with low risk of sensory loss. However, it has a 
mortality rate and so can only be performed in 
 medically fit patients. 
Those patients with multiple sclerosis-related 
TN are difficult to manage, as their tolerability 
of drugs is low and recurrence rates are much 
higher after surgical procedures [45]. 
Patients value having more information 
about TN both from healthcare professionals 
and other patients, and there is evidence that 
patient  support groups are helpful [35,50]. 
  Trigeminal neuropathic pain (TIN & AO)
There is no clear and universally accepted 
classification system and criteria for continu-
ous trigeminal pain conditions, some of which 
may be neuropathic in origin. As a result, it 
is difficult to determine the incidences of pain 
or sensory loss, and there is a lack of reliable 
epidemiologic and prognostic data. Some may 
develop chronic pain due to nerve injury after 
surgical trauma, such as tooth extraction or root 
canal therapy, or from more significant injuries 
such as trauma to the facial skeleton. Although 
dental surgery and orthognathic surgery is 
associated with sensory changes, the incidence 
of chronic pain remains unclear [51]. Persistent 
pain has been reported after endodontic (root 
canal) therapy to occur in 3 and 13% of cases, 
with significant risk associated with long and 
more severe preoperative tooth pain, history of 
chronic pain, previous painful orofacial treat-
ment and female gender [52]. It is now believed 
that AO may be a subset of trigeminal neuro-
pathic pain, and there are data suggesting that 
persistent idiopathic facial pain (PIFP; previ-
ously known as atypical facial pain) has ele-
ments of being a continuous pain condition 
but with less clear neuroanatomical boundaries 
[53,54]. Patients with PIFP and AO have been 
shown with neurophysiological and qualitative 
physiological tests to have some degree of sen-
sory dysfunction, including peri pheral and cen-
tral sensitization changes and even  nociceptive 
changes [55,56]. 
The proposed pathophysiology of neu-
ropathic pains of traumatic origin involves 
inflammatory and physical injury processes 
both in the PNS and CNS [57,58]. Inflammation 
occurs in response to nerve injury, which leads 
to ectopic electrophysiological activity and 
increased neuronal excitability [59]. Neuroplastic 
changes occur and continued afferent input 
leads to peripheral and central sensitization 
[60]. At the spinal level, a depletion of inhibi-
tory inter neurons occurs, and at the supraspinal 
level there is decreased inhibition and increased 
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facilitation of pain  mechanisms [61,62]. The net 
result of these processes are hyperalgesia, hyper-
sensitivity and allodynia.
The general characteristics of trigeminal 
neuro pathic pain include continuous burning 
pain, which may accompany paroxysms that are 
either evoked or spontaneous. Pain is of moderate 
to severe intensity, and can be accompanied by 
other sensory dysfunction such as hypoesthesia 
or numbness, and dysesthesia. The pain is in a 
neuroanatomically defined area, either corre-
sponding to a peripheral or central innervation 
territory. Patients may complain of swelling or 
the feeling of swelling, a foreign body, hot or cold, 
local redness or flushing.
Trigeminal neuropathic pain, TIN and AO 
have pain that is unilateral, corresponds to a 
dermatome, or may spread across dermatomes, 
depending on the extent of trauma. For post-
traumatic neuropathic pain, a history of previ-
ous dental treatment or trauma (i.e., suggested 
that this is within 3 months [12]) precedes pain 
onset, and may be accompanied by partial or 
complete sensory loss in the affected region. 
However, confirmation of a nerve lesion or disease 
by a specific test, study or surgical exploration is 
often impossible.
Diagnosis is based on a thorough history and 
careful examination, consisting of a neurologic 
examination, dental examination and evaluation 
of the temporomandibular joint and muscula-
ture. Quantitative sensory testing and other neu-
rophysiologic tests (e.g., blink reflex) may help 
distinguish traumatically induced or localized 
neuropathic pain from PIFP, however, there is 
considerable overlap in abnormalities between 
the two, and such tests are only available in spe-
cialist centers [55]. Imaging studies may be war-
ranted to rule out central processes such as tumor, 
vascular compression and infection.
Most of the accepted management of these 
conditions is based on expert opinion and case 
reports. Of the few RCTs, one for the treatment 
of AO comparing local anesthesia versus a placebo 
of normal saline showed some but not complete 
pain relief with the anesthetic [63]. Another RCT 
Table 2. Surgical management of trigeminal neuralgia.
Procedure/therapy Author (year) Efficacy/comments Adverse effects/morbidity/mortality Ref.
Peripheral – neurectomy, 
cryotherapy, alcohol 
injection
Eide et al. (1998)
Fardy et al. (1994)
Erdem and Alkan (2001)
Pradel et al. (2002)
Probability of being pain free after 
2 years: 22%
Pain often migrates to other branches 
necessitating drug use
Transient hematoma, edema
Mild sensory loss, dysesthesia
[101]
[102]
[103]
[104]
Radiofrequency 
thermorhizotomy
Zakrzewska (1991) Probability of being pain free after 
2 years: 68%
Probability of being pain free after 
5 years: 48%
Side effects related to temperature used
Sensory loss, dysesthesia, anesthesia 
dolorosa
Eye and masticatory problems
[105]
Percutaneous glycerol 
rhizotomy
Pollock (2005) Probability of being pain free after 
2 years: 63%
Probability of being pain free after 
5 years: 45%
Technically more demanding than 
radiofrequency thermorhizotomy
Sensory loss, dysesthesia [106]
Balloon 
microcompression
Lobato et al. (1990)
Correa and Teixeira 
(1998)
Probability of being pain free after 
2 years: 79%
Sensory loss, dysesthesia 
Masticatory problems
[107]
[108]
Microvascular 
decompression
Broggi et al. (2000)
Pollock and Ecker (2005)
Probability of being pain free after 
2 years: 81%
Probability of being pain free after 
5 years: 76%
Probability of being pain free after 
10 years: 70%
Perioperative complications (16%)
Transient cranial nerve dysfunction 
(IV, VI, VIII)
Permanent deafness (2%)
Mortality (0.2–0.4%)
[109]
[110]
Gamma knife stereotactic 
radiosurgery
Flickinger et al. (2001) Probability of being pain free after 
2 years: 58%
Late onset of relief
May only be partial relief
Sensory loss (7%) [111]
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found that intravenous infusion of ketamine and 
fentanyl was unable to produce an analgesic effect 
on spontaneous pain, but fentanyl reduced pain 
evoked by capsaicin [64]. Choices of medication 
should be based on proposed physiology, pres-
ence of other comorbidities and the patient’s use 
of other medications. Current accepted therapies 
are based on evidence and general guidelines for 
other neuropathic pain conditions and are sum-
marized in Table 3. For trigeminal neuropathic 
pain the consensus is that tricyclic antidepres-
sants, especially nortriptyline, and calcium chan-
nel blockers (a2d ligand modulators) such as 
gabapentin and pregabalin should be first-line 
therapies. Controversy does exist regarding the 
validity of evidence on gabapentin for off-label 
use with issues ranging from questionable and 
biased outcome reporting, to aggressive market-
ing by its manufacturer [65,66]. Selective serot-
onin/norepinephrine reuptake inhibitors and spe-
cific selective norepinephrine reuptake inhibitors 
are considered as second-line therapies [67]. By 
contrast, selective serotonin reuptake inhibitors 
have been found to have less efficacy, and has the 
undesired side effect of bruxism [68,69]. Opioids 
and tramadol are considered to be third-line 
therapies, considering the overlap of both neuro-
pathic and nociceptive mechanisms in trigeminal 
neuropathic pain, however, they should only be 
used on a limited basis with close monitoring by 
the prescribing provider. Topical medicaments 
have been advocated as first-line treatments for 
peripheral neuropathic pain, due to a lack of sys-
temic side effects. They may be delivered to the 
injured or affected sites with the aid of shields 
or custom made intraoral stents made of a soft 
splint material. In open labeled studies, topical 
amitriptyline was effective in peripheral neuro-
pathic pain, and capsaicin 0.025% cream was 
effective in oral neuropathic pain and traumau-
tic trigeminal dysesthesias [70,71]. The lidocaine 
patch (5%) has been shown in RCTs to be effec-
tive in the treatment of postherpetic neuralgia 
with minimal risk of side effects [72]. 
Table 3. Medical management of trigeminal neuropathic pain, based on guidelines for general neuropathic pain conditions.
Drug/procedure/therapy Author (year) Efficacy/comments Adverse effects/morbidity/mortality Ref.
Tricyclic antidepressants
Nortriptyline (25–150 mg daily)
Amitriptyline (25–150 mg daily)
Imipramine (25–150 mg daily)
Kishore-Kumar et al. (1990)
Watson et al. (1982)
Graff-Radford et al. (2000)
Proven in RCTs
Low cost
Doses on average 40 mg 
Minimum 6–8 weeks
Nortriptyline commonly used as 
fewer oral side effects 
Sedation, dry mouth, weight gain
Care in cardiac disease
[112]
[113]
[114]
SSNRIs
Duloxetine (30–120 mg daily) Goldstein et al. (2005)
Raskin et al. (2005)
Twice daily for 4 weeks
Not reported in facial pain 
Nausea [115]
[116]
Venlafaxine (37.5–225 mg daily) Forssell et al. (2004) Daily for 4–6 weeks
Venlafaxine had no benefit in 
small RCT for facial pain
[117]
Calcium channel blockers (a2d ligand modulators)
Gabapentin (600–3600 mg 
daily)
Moore et al. (2011) Three-times daily for 3–8 weeks
Improves sleep, few drug 
interactions
Sedation, ataxia, dizziness, edema, 
mood changes
Care in renal dysfunction
[118]
Pregabalin (300–600 mg daily) Frampton and Foster 
(2005)
Twice daily for 4 weeks
Useful in those with concomitant 
anxiety
[119]
Tramadol (100–400 mg daily) Norrbrink and Lundeberg 
(2009)
Rarely used in trigeminal pain Sedation, nausea, constipation [120]
Topical (5% lidocaine patch) Davies and Galer (2004) RCTs show efficacy for 
postherpetic neuralgia
Difficult to apply on the face 
Three patches and 12 h maximum
Use for 3 weeks
Erythema, rash [72]
RCT: Randomized controlled trial; SSNRI: Selective serotonin/norepinephrine reuptake inhibitor. 
Data taken from [54].
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The role of surgical interventions for trigemi-
nal neuropathies remains unclear due to a lack 
of good evidence with prospective controlled 
trials. Sympathetic blockade and sympathetic 
radio frequency remain unproven, and their use 
may be ineffectual due to recent findings show-
ing a lack of activation of nociceptors related 
to sympathetic discharge in chronic neuro-
pathic pain patients [73]. Other proposed surgi-
cal interventions include using a gamma knife 
that targets the sphenopalatine ganglion and 
brain stimulation. Noninvasive electrical brain 
stimulation techniques, including magnetic, 
electrical and direct current stimulation, have 
been shown to be effective for certain chronic 
pain conditions and may have applicability [74].
Burning mouth syndrome
Burning mouth syndrome (also known as 
stomato dynia) is an oral mucosal pain con-
dition that is chronic, and absent of identifi-
able causative lesions, conditions or diseases. 
Reported prevalence in general populations 
varies from 1 to 15% according to diagnostic 
criteria, however, many studies include people 
with the symptom of  burning mouth rather 
than true BMS as defined above [75].
Once thought to be purely psychologic in 
etio logy, there is now increasing evidence of 
neuropathic elements of this disorder [76]. 
Supporting that hypothesis is the frequent pres-
ence of dysgeusia with pain in BMS patients. 
The taste nervous system is thought to provide 
central inhibitory control over afferent fibers 
responsible for pain in both the glossopharyn-
geal and trigeminal nerves. This is supported 
by the findings that anesthesia of the chorda 
tympani causes increased pain evoked by cap-
saicin on the contralateral anterior tongue, 
topical administration of lidocaine to affected 
areas increases oral burning, in the same man-
ner as in phantom limb pain, and hypofunc-
tion of the chorda tympani can lead to taste 
disturbance [77]. A relation has been established 
between the genetic predisposition of ‘super-
tasters’, with the ability to elicit a bitter taste 
sensation with 6-n-propyl-thiouracil, and inten-
sification of pain. There is also a thought that 
dysregulation, impairment or decrease of site-
specific (i.e., oral) neuro active steroids that have 
a neuroprotective effect, results in symptoma-
tology of BMS [78]. This may account for the 
predilection towards postmenopausal women 
and for the comorbidities of stress, anxiety and 
depression among BMS patients, all factors that 
change adrenal production of steroids.
Women are three- to 20-fold more affected 
than men, usually at menopausal or postmeno-
pausal age. Onset is spontaneous, with con-
stant burning sensation and no paroxysmal 
components. This may be accompanied by tin-
gling, dyesthesias and dysgeusia (altered taste). 
Location is mainly bilateral, with anterior 
tongue involvement in most cases, but also the 
lips, palate and pharynx can be involved. Pain 
intensity is variable among patients, ranging 
from both extremes in the spectrum from mild 
discomfort, to excruciating pain. Patients often 
report high scores in psychometric tests for 
anxiety and depression, but no causal relation-
ship has been found. There is no precise infor-
mation on the clinical course and prognosis of 
BMS. Improvement has been cited in one-half 
to two-thirds of patients within 6–7 years of 
onset, with spontaneous remission rates of 20% 
in that time frame [76,79]. One clinical study 
found spontaneous remission to occur in 3% 
of patients within 5 years after diagnosis [76,80].
Diagnosis is obtained based on a thorough 
history and the elimination of local (e.g., candi-
diasis, herpes, hyposalivation, allergy, mucosal 
lesions) or systemic factors (e.g., vitamin defi-
ciencies, diabetes, hypothyroidism, medica-
tions [e.g., angiotensin-converting enzyme 
inhibitors], autoimmune disorders) as causes 
of their symptoms. Diagnostic tests include 
blood tests (i.e., hematological, biochemical 
and immunologic) and microbial testing (i.e., 
viral or fungal culture).
There are very few RCTs for BMS, as sum-
marized in Table  4 [81,82]. Upon diagnosis of 
BMS, patients should be reassured about the 
physiological basis of their condition despite 
lack of identifiable organic causes, and that it is 
not due to malignant processes. Treatment for 
BMS is primarily pharmacological, with psycho-
logical support if indicated in refractory cases 
with high anxiety or depression. One controlled 
study showed that cognitive behavioral therapy 
of weekly 1 h sessions for 4 months reduced pain 
intensity for up to 6 months in BMS patients 
[83], however, no other studies on this approach 
have been published in recent years.
Conclusion & future perspective
Although therapies for trigeminal neuropathic 
pains should be targeted towards specif ic 
mechanisms, uncertainties preclude definite 
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treatment algorithms. Therefore, there is a need 
to further define pathophysiology of trigeminal 
neuropathic pains, with the idea that multiple 
mechanisms might be involved. In addition, 
consistent classification, taxonomy, criteria, 
phenotyping and definitions of outcome meas-
ures of the various conditions are needed in 
order to carry out clinical trials. Among clini-
cal trials, there is a need for comparisons of dif-
ferent medications available, both individually 
and in combinations. Providers must translate 
the effectiveness of clinical trials into their 
practice, as often noneffective medications, 
subtherapeutic dosages or inadequate times 
for trial therapy lead to treatment failure, and 
ultimately frustration on the part of providers 
and patients. In addition, patient education 
and supportive  adjunctive therapies and meas-
ures should be emphasized and included in the 
overall treatment plan. Patient understanding 
and informed reassurance of their condition 
leads to better management, with improved 
coping strategies, more compliance and proper 
utilization of  treatment modalities.
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Table 4. Management of burning mouth syndrome.
Drug/procedure/therapy Author (year) Efficacy/comments Adverse effects/morbidity/mortality Ref.
Evidence from RCTs
a-lipoic acid 
(200–600 mg daily)
Femiano et al. (2000)
Femiano et al. (2002)
Femiano and Scully (2002)
Femiano et al. (2004)
Use daily for 3 months
NNT 1.6–3.3
Earlier trials from same center and not 
all double blind
Newer RCT shows no benefit
None reported [121]
[122]
[123]
[124]
Clonazepam (1–3 mg 
topical or 0.25–1 mg 
systemic)
Gremeau-Richard et al. 
(2004)
Topical – suck for 3 min for 2 weeks
Systemic – take at bedtime
Shows some benefit
Systemic – marked drowsiness, 
addictive
[125]
Capsaicin systemic
(0.25% capsule  
three-times daily)
Petruzzi et al. (2004) NNT 1–2
Poor quality trial
Side-effect profile limits its use
Gastric pain in 32% [126]
SSRIs
Amisulpride (50 mg daily)
Paroxetine (20 mg daily)
Sertraline (50 mg daily)
Maina et al. (2002) Use for a few weeks
Reduced pain severity in one single-
blind, nonplacebo-controlled RCT
Rarely used in practice
Mild, nonspecific [127]
Cognitive behavior 
therapy
Bergdahl et al. (1995) 1 h for 12–15 weeks
Single-blind RCT
More effective than no treatment
[83]
No evidence from RCTs
Calcium channel blockers (a2d ligand modulators)
Gabapentin  
(300–2400 mg daily)
White et al. (2004)
Heckmann et al. (2006)
Limited effectiveness Ataxia, dizziness, drowsiness, nausea, 
headache, weight gain
Care in renal dysfunction
[128]
[129]
Pregabalin  
(100–300 mg daily)
Lopez et al. (2009) May be effective
Improves anxiety and sleep
Dizziness, tiredness, headaches, 
peripheral edema
Care in renal dysfunction
[130]
Tricyclic antidepressants
Nortriptyline  
(20–50 mg daily)
O’Connor and Dworkin 
(2009)
6–8-week use
May be effective
Sedation, dry mouth, weight gain
Use with care in cardiac disease
[67]
NNT: Number needed to treat; RCT: Randomized controlled trial; SSRI: Selective serotonin reuptake inhibitor.
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